Royalty Pharma (RPRX) Q1 FY26 earnings call: guidance and Q&A

How much of the $5 billion 2030 portfolio receipts target is de-risked, and how much comes from already commercialized assets?

Management expressed high confidence in meeting or exceeding the $5 billion 2030 target, citing strong portfolio performance and recent deals, but did not provide a specific breakdown of de-risked vs. commercialized assets.

“Yes. So Hardik, we feel like we're really on track to meet or exceed that target. The portfolio is doing really well. We've had a lot of positive developments. We've executed some great deals. So we haven't gotten into specifics on that at this point, but I feel like we're very much on track or very confident in meeting or exceeding that long-term guidance.”

asked by Hardik Parikh (JPMorgan) · answered by Terrance Coyne

What caused the arbitration push-out? What advantage does MYQORZO's non-obstructive HCM approval offer over Camzyos, and was it assumed in valuation? Has frexalimab's competitive positioning in MS changed due to oral BTK inhibitors?

The arbitration push-out was due to panel availability. MYQORZO's non-obstructive HCM data was not in the original base thesis but provides a broader label and patient population, offering upside. Frexalimab's positioning in MS remains strong, as it addresses an unmet need for novel mechanisms beyond B-cell therapies.

“The adding non-obstructive to label can only be helpful, right? It gives a broader label. It provides another patient population for doctors to use the for doctors to use the medicine in. And overall, we'll certainly be helpful in the launch and certainly upside to our original estimates when we made that partnership with Cytokinetics.”

asked by Michael Nedelcovych (TD Cowen) · answered by Terrance Coyne

Is Royalty Pharma at the upper end of its leverage range, and is there a capacity constraint for future capital deployment? Are there opportunities to add additional royalty investments to rapidly launching drugs like Rev Med or Servier?

The company has low leverage (2.9x total debt to adjusted EBITDA) and significant financial flexibility (~$4 billion) for future investments. While additional tranches for Revolution Medicines are at their option, the company is open to deploying more capital for successful products, but no specific plans for additional investments based solely on rapid launch pace were mentioned.

“As a reminder, the Rev Med deal, we've done $500 million of $1.25 billion of synthetic royalties. There are additional opportunities that will come at FDA approval, which we expect to see this year. And then with a certain sales milestone and then there's a label expansion later on. So there are other opportunities However, the future tranches are all at the option of revolution medicine.”

asked by Geoffrey Meacham (Citi) · answered by Terrance Coyne

How is MFN risk for OUS launches being factored into underwriting? Do IRR expectations for R&D co-funding deals differ from traditional royalty acquisitions, and do they include capping mechanisms?

MFN risk is being considered through scenario analysis, acknowledging its novelty. IRR expectations for R&D co-funding are consistent with the company's publicly communicated targets (greater than low double digits for unapproved products). The company's philosophy is to benefit from the full potential of products, and while structural features vary, the aim is to ensure appropriate risk-adjusted returns.

“I think as Chris outlined, our -- the answer to your question is no. We have said that our return expectations for products that are not approved are kind of greater than the low double digits. And so we certainly see we certainly see returns in the IRR co-funding is very consistent with what we've communicated publicly in terms of return expectations.”

asked by Jason Gerberry (Bank of America) · answered by Marshall Urist

Does MYQORZO's positive non-obstructive data create a halo effect for its obstructive launch? How does consolidation among smaller royalty players impact competition?

MYQORZO's positive non-obstructive data is seen as a tailwind, providing a broader label and patient experience that will help the overall launch. Consolidation among smaller royalty players is not seen as a significant change to competition, as Royalty Pharma has distinct advantages (scale, tax structure, lower cost of capital) and welcomes competition as it expands the market.

“Yes. So on MYQORZO, certainly, yes, we believe that the positive data yesterday provide an advantage to ecopipam in the marketplace, having a broader label, having experience in a broader selection of patients. can really only help the medicine as Cytokinetics launches it.”

asked by Unknown Analyst (UBS) · answered by Marshall Urist

Will the growing R&D co-funding focus shift the overall portfolio complexion? What is the update on the China market, types of assets, and timing for the first deal?

R&D co-funding could lead to a greater percentage of capital deployed in development-stage assets, but the company will remain disciplined. In China, the company is actively building a platform, hired Ken Sun as Head of Asia, and is tracking out-licensing opportunities, with the BeOne transaction serving as evidence of monetization potential for Chinese companies.

“In terms of China, I'd just remind you, Ben, obviously, we did the transaction with them last year, that for Imdelltra, which is roughly $900 million, obviously, that caught the attention of a lot of companies in China that look at BeOne as a great originally coming out of China. We hired Ken Sun. He starts actually next week. He was the former Head of Asia at Morgan Stanley.”

asked by Nick Jennings (Goldman Sachs) · answered by Christopher Hite

What is the perspective on J&J DUET data and its implications for the Tremfya tail? Can you provide case studies or efficiencies from AI implementation?

The J&J 4804 deal is a strong example of participating in a blockbuster market. The DUET data for 4804 is exciting for a refractory patient population, representing a rapidly growing market. The Tremfya royalty, based on separate IP, will expire in the early 2030s, so 4804 creates a new royalty. AI is crucial, with significant data investments (200M claims, 44M EMRs) used for internal analysis and partner insights. Lucas Glass was hired as Head of AI to automate diligence and strengthen investment evaluation.

“But one of the very exciting things for Royalty Pharma is to actually use data with our partners and share insights that we gain as we do our analysis. And as we follow the ecosystem, and we think that is a differentiating aspect that is important to us because we don't see ourselves like others as purely cattle price but we see ourselves as partners with the companies that we're partnering with, where we can provide we add value by sharing data and insights for them, and they appreciate that.”

asked by Daniel Ziment (Morgan Stanley) · answered by Pablo Legorreta

How will capital deployment split between R&D co-funding and traditional royalty investments, especially with a focus on larger checks? What are the IRR expectations for big pharma R&D co-funding, specifically for J&J 4804?

Capital allocation is flexible, driven by attractive, differentiated products, regardless of source. The company has significant capacity (up to $30 billion long-term, $20 billion over 5 years) and new growth drivers in China and big pharma R&D co-funding were not fully included in prior guidance. IRR expectations for R&D co-funding are consistent with targets for unapproved products (greater than low double digits), and the J&J 4804 deal is a good example of this.

“And then the second one is deal with big pharma. Again, we were super [ concerned ] and didn't really include in our forecast of business plan guidance, much of any capital deployment with big pharma, but that is definitely becoming a big opportunity for us and one that we're very, very excited.”

asked by Umer Raffat (Evercore) · answered by Pablo Legorreta